Citation Impact
Citing Papers
Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100
2012
Phase II Trial of Dasatinib in Patients with Metastatic Breast Cancer Using Real-Time Pharmacodynamic Tissue Biomarkers of Src Inhibition to Escalate Dosing
2011
VIRTUS: a pipeline for comprehensive virus analysis from conventional RNA-seq data
2020 StandoutNobel
c‐Src, Insulin‐Like Growth Factor I Receptor, G‐Protein‐Coupled Receptor Kinases and Focal Adhesion Kinase are Enriched Into Prostate Cancer Cell Exosomes
2016
Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
2011
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
2016
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor
2014 StandoutNobel
Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis
2015
A view on drug resistance in cancer
2019 StandoutNature
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
Epithelial-Mesenchymal Transitions in Development and Disease
2009 Standout
The emerging role of lncRNAs in cancer
2015 Standout
Nomograms in oncology: more than meets the eye
2015 Standout
Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
2012
Trends in GPCR drug discovery: new agents, targets and indications
2017 Standout
Long Noncoding RNAs in Cancer Pathways
2016 Standout
The biology and function of fibroblasts in cancer
2016 Standout
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
2016 StandoutNobel
Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity
2018
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
2012
Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy
2013
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
2012 Nobel
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
2017 Standout
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Targeted therapies in bladder cancer: an overview of in vivo research
2015
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
2016
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
New Therapeutics to Treat Castrate‐Resistant Prostate Cancer
2013
Bladder cancer
2016 Standout
Mortality due to cancer treatment delay: systematic review and meta-analysis
2020 Standout
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
2016 Standout
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
2010 Standout
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Emerging Biological Principles of Metastasis
2017 Standout
Androgen action and metabolism in prostate cancer
2012
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
EMT: 2016
2016 Standout
Promise and pitfalls of quantitative imaging in oncology clinical trials
2012
Targeting metastasis
2016
Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study
2013
What Is the Significance of Variant Histology in Urothelial Carcinoma?
2019
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
2015 Standout
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
2018
The PI3K Pathway in Human Disease
2017 Standout
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
2012
Drug safety is a barrier to the discovery and development of new androgen receptor antagonists
2010
Clinicians Versus Nomogram: Predicting Future Technetium-99m Bone Scan Positivity in Patients With Rising Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer
2013
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
2014 Standout
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
2014 StandoutNobel
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
2015
Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review
2017
Molecular biology and targeted therapies for urothelial carcinoma
2015
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
2017 Standout
A review of tasquinimod in the treatment of advanced prostate cancer
2013
Immunotherapy for the Treatment of Urothelial Carcinoma
2016
Exosomes
2019 Standout
EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals
2015 Standout
Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond—A Comprehensive Review of the Current Literature
2015
Enzalutamide for the Treatment of Prostate Cancer: Results and Implications of the AFFIRM Trial
2014
New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway
2011
Enzalutamide: A Novel Antiandrogen for Patients with Castrate-Resistant Prostate Cancer
2013
Bladder Cancer
2020 Standout
Diabetes and Cancer
2010 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
The evolution of antiandrogens: MDV3100 comes of age
2012
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis
2016
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials
2017
Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
2019
Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies
2010
Current Status of Src Inhibitors in Solid Tumor Malignancies
2011
Cancer treatment and survivorship statistics, 2016
2016 Standout
Antibody-Drug Conjugates in Urothelial Carcinomas
2020
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment
2022
Olaparib for Metastatic Castration-Resistant Prostate Cancer
2020
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer
2010
A Clinical Study of Lupron Depot in the Treatment of Women with Alzheimer's Disease: Preservation of Cognitive Function in Patients Taking an Acetylcholinesterase Inhibitor and Treated with High Dose Lupron Over 48 Weeks
2015
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
2020
EMT, CTCs and CSCs in tumor relapse and drug-resistance
2015
Tunable protein synthesis by transcript isoforms in human cells
2016 StandoutNobel
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Second-Line Systemic Therapy for Metastatic Urothelial Carcinoma of the Bladder
2013
A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone Metastases
2013
Works of Evan Y. Yu being referenced
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
2019
A phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis
2007
Systematic Review: Targeting HER2 in Bladder Cancer
2019
C11-Acetate and F-18 FDG PET for Men With Prostate Cancer Bone Metastases
2011
Challenges and Recommendations for Early Identification of Metastatic Disease in Prostate Cancer
2014
Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy
2014
Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer
2011
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis
2009
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
2010
Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer
2016
Persistent androgen receptor addiction in castration-resistant prostate cancer
2015
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel
2015
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
2013
Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE).
2012
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer
2009
Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.
2019
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer
2015
Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
2010
Long-Term Dynamics of Bone Mineral Density During Intermittent Androgen Deprivation for Men With Nonmetastatic, Hormone-Sensitive Prostate Cancer
2012
7004 Final results of a randomized phase II study of OGX-011 (OGX) in combination with docetaxel (DOC)/prednisone versus docetaxel/prednisone in patients with metastatic castration resistant prostate cancer (CRPC)
2009
Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer
2012
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma
2014
1099 LONG-TERM EFFICACY RESULTS FROM THE PHASE 1-2 STUDY OF MDV3100 IN PRE- AND POST-DOCETAXEL ADVANCED PROSTATE CANCER
2011
Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate
2016
Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
2022
IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).
2016
Delays in radical cystectomy for muscle‐invasive bladder cancer
2019
Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
2013
Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826).
2011
Abstract PD3-07: Trastuzumab deruxtecan (T-DXd; DS-8201) with nivolumab in patients with HER2-expressing, advanced breast cancer: A 2-part, phase 1b, multicenter, open-label study
2021
Patient (pt) characteristics, treatment patterns, outcomes and prognostic factors in plasmacytoid urothelial carcinoma (PUC).
2019
Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
2011